Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Novo Nordisk Plans GLP-1 Analogue Expansion To Treat Diabetes, Obesity

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm on track for liraglutide U.S., EU filings in second quarter; Japan filing in third quarter.

You may also be interested in...



Novo Nordisk, Emisphere Collaborate To Propel Oral GLP-1 Compounds In R&D

Emisphere carrier technology may be applied to other compounds as well.

Novo Nordisk, Emisphere Collaborate To Propel Oral GLP-1 Compounds In R&D

Emisphere carrier technology may be applied to other compounds as well.

Novo Nordisk Halts Development Of AERx, Its Phase III Fast-Acting Inhaled Insulin Product

Lilly/Alkermes' AIR and MannKind's Technosphere Insulin System still aim for market where Exubera failed.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS066829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By